Scholarlink

<p>Laryngeal squamous cell carcinomas (LSCCs) was a frequent malignancy in upper aerodigestive tract. The lack of non-invasive biomarkers for early diagnosis has led to unfavorable prognosis. We firstly identified methylation biomarkers from TCGA and GEO databases. We further validated the diagnostic performance by utilizing blood samples obtained from 43 LSCCs and 50 normal controls (NCs). The <i>HOXD10</i> cg10364040 was hypermethylated in tumors compared with NCs (<i>P</i> &lt; 0.01), with an area under the curve (AUC) greater than 0.90 in each public database. In clinical validation phase, <i>HOXD10</i> cg10364040 methylation was able to discriminate LSCCs from NCs with high accuracy (AUC = 0.767, sensitivity: 72.1%, specificity: 82.0%), and exhibited greater sensitivity (85.0%) and specificity (86.0%) in stage I patients than in NCs (AUC = 0.864). In summary, we firstly identified cg10364040 as a novel diagnosis biomarker of LSCC and confirmed it as a noninvasive biomarker in clinical.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Noninvasive early diagnosis of laryngeal squamous cell carcinoma (LSCC) revealing the high-performance potential of the HOXD10 gene monomethylated locus: a case–control study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月12日

查看全文
  • Xiaoyang Gong,
  • Zhaoyi Lu,
  • Zihang Zhu,
  • Qin Zhang,
  • Haibing Chen,
  • Han Zhou,
  • Qianqian Duan,
  • Chan Zhu,
  • Dongsheng Chen,
  • Lei Cheng,
  • Xin Cao,
  • Xi Chen

摘要

Laryngeal squamous cell carcinomas (LSCCs) was a frequent malignancy in upper aerodigestive tract. The lack of non-invasive biomarkers for early diagnosis has led to unfavorable prognosis. We firstly identified methylation biomarkers from TCGA and GEO databases. We further validated the diagnostic performance by utilizing blood samples obtained from 43 LSCCs and 50 normal controls (NCs). The HOXD10 cg10364040 was hypermethylated in tumors compared with NCs (P < 0.01), with an area under the curve (AUC) greater than 0.90 in each public database. In clinical validation phase, HOXD10 cg10364040 methylation was able to discriminate LSCCs from NCs with high accuracy (AUC = 0.767, sensitivity: 72.1%, specificity: 82.0%), and exhibited greater sensitivity (85.0%) and specificity (86.0%) in stage I patients than in NCs (AUC = 0.864). In summary, we firstly identified cg10364040 as a novel diagnosis biomarker of LSCC and confirmed it as a noninvasive biomarker in clinical.